We further examined a separate cohort of patients with JIA who developed flare or remained in remission 8 months into withdrawal of therapy, and verified the overt presence of T-effector diversification (CD45RA−TNFα+IL-6+) during flare. The gene discussed is IL6; the disease is juvenile idiopathic arthritis.